Functional characterization of Narc 1, a novel proteinase related to proteinase K
about
Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularlyThe proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modificationsSelf-association of human PCSK9 correlates with its LDLR-degrading activitySecreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic miceAnnexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levelsAdenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotypeProprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseasesCholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemiaTrafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal DomainMolecular biology of PCSK9: its role in LDL metabolismStructural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemiaThe self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domainAntagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 CellsPCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the futureStructural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptorCatalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cellsExpression and localization of PCSK9 in rat hepatic cellsWild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cellsEvidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate speciesEfficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemiaMolecular population genetics of PCSK9: a signature of recent positive selection.Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.Proprotein convertases in high-density lipoprotein metabolism.The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis.A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygoteRelationships between genetic polymorphisms of E670G in PCSK9 gene and coronary artery disease: a meta-analysisPCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis.Autosomal dominant hypercholesterolemia: needs for early diagnosis and cascade screening in the tunisian population.Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.Dysregulation of the Low-Density Lipoprotein Receptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury.Transcriptome profiling and genome-wide DNA binding define the differential role of fenretinide and all-trans RA in regulating the death and survival of human hepatocellular carcinoma Huh7 cells.Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.Prohaptoglobin is proteolytically cleaved in the endoplasmic reticulum by the complement C1r-like protein.Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.PCSK9: an emerging target for treatment of hypercholesterolemia.Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statins.
P2860
Q24298534-7E7832BC-741C-4F8C-A260-E0D07B9973EFQ24299848-C09570E0-F317-4961-9C90-D72EE021F74FQ24306591-7C8257A5-05AC-4E45-A40A-E0A22FF0B353Q24311328-842D2408-BF85-43BF-9999-C8B14D9593FEQ24313575-90BE47FD-FD34-42D5-828F-221AA38459E4Q24563948-4D387A00-33FE-4BB1-A6C2-BA9E56C2289EQ27009477-237B63A1-B17F-4FF8-9385-160FE7DAA1EAQ27013494-FC14F8FE-DD0B-49D1-9D58-B8A148140D64Q27339783-3A5F2884-8EC1-436B-BD24-2D737ABF3F46Q27488922-CC88C8B8-A20F-407C-AA13-6E077C450A28Q27644461-C287510E-3310-4582-822A-0E4524734297Q27647905-5AF5900D-4D2C-4ADB-A914-D85929795C87Q27653836-FFA84715-870F-47F0-B25D-6659E172D14EQ28083595-FE443C14-C109-4CD7-887F-DC6402DBC634Q28292154-FD94014C-6DFE-447A-9263-4C31DB8AC283Q28304381-350C5850-5FE4-40B2-BFB0-28258F8D84D7Q28568944-5E3DAEF0-B957-4397-B73B-EA23D1803AB1Q28585300-33094670-2DE9-4FEE-B343-F110A77A8074Q28756853-A2634C53-60E0-49FD-BEFD-F814650FA76AQ33728343-4BBAB096-DB3A-4B06-90DB-6BE3F7F17D81Q33743727-673190FB-3DA1-41F0-97D1-9DE68A285A34Q33767310-B2E68319-83A8-44CC-AE63-13DEB80B8D7CQ34021096-6EBE6B1A-B022-4E17-B4E2-DE219EC522ACQ34256139-8458FA47-FA2D-41A8-80D9-AF293B86D475Q34355679-195707A8-AB97-46B4-AD4B-23E868BC561AQ34399014-74630814-DFC3-4969-844D-D1EA3FB8AC63Q34430377-9B5E3A26-5636-4CA3-9C9B-029FB5D02A14Q35015811-7E6DAAD6-2A46-42C8-BA0A-0961AAF6FCE0Q36182994-0E5F9E0E-B026-423C-BE03-F4020B89EB83Q36197840-92ADDE5D-9978-4C88-BFA3-7999E351FD56Q36292659-A4458627-78C7-4A7E-9D6E-5CA3284EF5F0Q36634114-B048E564-5FB2-469F-AED8-AF5FB6A9BAC0Q36708550-CE971C7B-C38B-4D27-B8B8-5EB24367A801Q36727852-4331E773-7530-41E5-AB04-35AE45825DA3Q37378329-397A5361-1ADA-4B99-B315-1E2B8CCAF9F6Q37384902-AE3BBBD5-2C32-4134-8F6C-2D46B8D821FFQ37569256-AD1EC61E-7E07-41DF-8ABA-EAC869A036B1Q37688760-9FB4C9A6-8153-4EF5-B42E-03B5E13C5DBAQ37825903-99FDF126-72B3-4FC2-8A6F-7575E1B69BE9Q37972887-1E1B5524-9AF5-4994-834F-362E59C3840C
P2860
Functional characterization of Narc 1, a novel proteinase related to proteinase K
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Functional characterization of Narc 1, a novel proteinase related to proteinase K
@ast
Functional characterization of Narc 1, a novel proteinase related to proteinase K
@en
Functional characterization of Narc 1, a novel proteinase related to proteinase K
@nl
type
label
Functional characterization of Narc 1, a novel proteinase related to proteinase K
@ast
Functional characterization of Narc 1, a novel proteinase related to proteinase K
@en
Functional characterization of Narc 1, a novel proteinase related to proteinase K
@nl
prefLabel
Functional characterization of Narc 1, a novel proteinase related to proteinase K
@ast
Functional characterization of Narc 1, a novel proteinase related to proteinase K
@en
Functional characterization of Narc 1, a novel proteinase related to proteinase K
@nl
P2093
P3181
P1476
Functional characterization of Narc 1, a novel proteinase related to proteinase K
@en
P2093
Andrew Wood
Bradley A Ozenberger
Brendan Bingham
C Frederick Lo
J Steven Jacobsen
Jeffrey D Kennedy
Jill M Grenier
Kodangattil Sreekumar
Lillian W Chiang
P3181
P356
10.1016/J.ABB.2003.09.011
P407
P577
2003-12-01T00:00:00Z